In agreement with these findings, we also found that the primary CD8+ T cell response to the mRNA LNP COVID vaccine was increased early after vaccination in MS patients with the lowest frequency of circulating B cells (13). The gene discussed is CD8A; the disease is myeloid sarcoma.